KIROMIC BIOPHARMA INC (KRBP)       0.29  -0.01 (-3.17%)

0.29  -0.01 (-3.17%)

US4976341051 - Common Stock - After market: 0.29 0 (0%)

KIROMIC BIOPHARMA INC0.29

NASDAQ:KRBP (9/30/2022, 7:00:03 PM)-0.01 (-3.17%)

After market: 0.29 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-12 2022-08-12/amc Earnings (Next) 03-09 2023-03-09
Ins Owners 16.26% Inst Owners 2.84%
Market Cap 4.59M Shares 15.84M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO 10-16 2020-10-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KRBP Daily chart

Company Profile

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is focused on discovering, developing and commercializing immuno-oncology applications through its product pipeline. The company is developing a range of product candidates for the treatment of blood cancers and solid tumors. Its lead product candidates include ALEXIS-PRO-1 and ALEXIS-ISO-1. The firm is developing its brand of chimeric antigen receptor (CAR) T cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). The ALEXIS platform of products has been designed to incorporate its Diamond target discovery platform into an off the shelf gamma delta T cell therapy that address the metastatic and progressive locally advanced solid malignancies, including ovarian, malignant pleural mesothelioma and multiple other indications as well. Its Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells.

Company Info

KIROMIC BIOPHARMA INC

7707 Fannin St., Suite 140

Houston TEXAS 77054

P: 18329684888.0

CEO: Maurizio Chiriva-Internati

Employees: 59

Website: https://kiromic.com/

KRBP News

News Imagean hour ago - Kessler Topaz Meltzer & Check, LLPKRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed...

News Image3 hours ago - NewMediaWireKRBP DEADLINE ALERT: ROSEN, A TOP RANKED FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image2 days ago - Bragar Eagel & Squire, P.C.KIROMIC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the FirmNews Image2 days ago - Rosen Law Firm, P.A.KRBP TUESDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

/PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i)...

News Image2 days ago - Jakubowitz LawKRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc....

News Image3 days ago - SBWireKiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Deadline in Lawsuit on October 4, 2022

San Diego, CA -- (SBWIRE) -- 09/29/2022 -- A deadline is coming up on October 4, 2022 in the lawsuit filed for certain investors of Kiromic BioPharma, Inc. (NASDAQ:KRBP).

KRBP Twits

Here you can normally see the latest stock twits on KRBP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example